Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CDK9 | P50750 | 3/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CCNK | O75909 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | PRKACA | P17612 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525833 | 0.84 | CDK2 (0.37) | GRM4CDK2CDK9CCNT1CCNK | |
| SCHEMBL13535278 | 0.83 | TRPV1 (0.39) | CCNB2CDK1RETCCNB1CCNB3 | |
| SCHEMBL9882401 | 0.80 | RPS6KA5 (0.35) | GRM4CDK2CDK9CDC7MAP4K4 | |
| SCHEMBL10458860 | 0.77 | CCNK (0.46) | CDK2CDK9CCNT1CCNKCCNE1 | |
| SCHEMBL10459366 | 0.77 | PRKCA (0.40) | CDK2CDK9CCNT1CCNKCCNE1 | |
| SCHEMBL9882360 | 0.77 | CCNT1 (0.43) | CDK2CDK9CCNT1CCNKCCNE1 | |
| SCHEMBL10459336 | 0.77 | CDK2 (0.35) | CDK2CDK9CCNT1CCNKCCNE1 | |
| SCHEMBL10458867 | 0.77 | CDK2 (0.33) | CDK2CDK9CCNT1CCNKCCNE1 | |
| SCHEMBL9881935 | 0.77 | PRKCQ (0.53) | CDK2CDK9CCNT1CCNKCCNE1 | |
| SCHEMBL10459483 | 0.77 | GRM4 (0.38) | GRM4ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-9029546-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029546-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2318407-B1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2318407-B1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-07-19 | — | — | US | disclosed |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-07-19 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| WO-2010011756-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011756-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011772-A2 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | GRM4 4003/4885CDK2 105/4885CDK9 161/4885 |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | GRM4 4003/4885CDK2 105/4885CDK9 161/4885 |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | GRM4 3570/4885CDK2 77/4885CDK9 178/4885 |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | GRM4 3570/4885CDK2 77/4885CDK9 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.